The estimated Net Worth of Abhijeet J Lele is at least 57.3 千$ dollars as of 29 March 2019. Abhijeet Lele owns over 20,000 units of Agile Therapeutics Inc stock worth over 57,303$ and over the last 11 years Abhijeet sold AGRX stock worth over 0$.
Abhijeet has made over 1 trades of the Agile Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Abhijeet bought 20,000 units of AGRX stock worth 30,800$ on 29 March 2019.
The largest trade Abhijeet's ever made was buying 20,000 units of Agile Therapeutics Inc stock on 29 March 2019 worth over 30,800$. On average, Abhijeet trades about 2,857 units every 0 days since 2014. As of 29 March 2019 Abhijeet still owns at least 37,949 units of Agile Therapeutics Inc stock.
You can see the complete history of Abhijeet Lele stock trades at the bottom of the page.
Abhijeet's mailing address filed with the SEC is 101, Poor Farm Road, Princeton, Mercer County, New Jersey, 08540, United States.
Over the last 11 years, insiders at Agile Therapeutics Inc have traded over 2,369,944$ worth of Agile Therapeutics Inc stock and bought 24,967,253 units worth 79,522,957$ . The most active insiders traders include Advisors Llcperceptive Life...、Ab Investor、Capital Iii Llc Care Capita.... On average, Agile Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of 1,032,678$. The most recent stock trade was executed by Alfred Altomari on 26 August 2022, trading 50,000 units of AGRX stock currently worth 22,500$.
agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Agile Therapeutics Inc executives and other stock owners filed with the SEC include: